Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

New research from an international team of scientists could offer doctors a new way to detect and monitor progressive lung diseases – and may also shed light on the fundamental causes of those ...

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by ...

The therapeutic drug pirfenidone has been found to be a potential treatment for rheumatoid arthritis-associated interstitial lung disease by researchers at Baylor College of Medicine, National Jewish ...

Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of "a partially-blinded ...

A new development in wireless sensing technology that can reliably screen for five common pulmonary diseases could lead to ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider Jeffrey J. Swigris, ...

When inflammation in the body goes unchecked, it can cause fibrosis, or tissue scarring that may lead to organ dysfunction or ...

Active rash, interstitial lung disease and elevated neutrophil to lymphocyte ratio were independently associated with ...